ANEB vs. DERM, ASRT, LPTX, SLS, IFRX, TPST, MNOV, CUE, SPRO, and YS
Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Journey Medical (DERM), Assertio (ASRT), Leap Therapeutics (LPTX), SELLAS Life Sciences Group (SLS), InflaRx (IFRX), Tempest Therapeutics (TPST), MediciNova (MNOV), Cue Biopharma (CUE), Spero Therapeutics (SPRO), and YS Biopharma (YS). These companies are all part of the "pharmaceutical preparations" industry.
Anebulo Pharmaceuticals (NASDAQ:ANEB) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
Anebulo Pharmaceuticals currently has a consensus target price of $6.67, suggesting a potential upside of 151.57%. Journey Medical has a consensus target price of $8.50, suggesting a potential upside of 140.11%. Given Anebulo Pharmaceuticals' higher possible upside, research analysts clearly believe Anebulo Pharmaceuticals is more favorable than Journey Medical.
In the previous week, Anebulo Pharmaceuticals and Anebulo Pharmaceuticals both had 1 articles in the media. Journey Medical's average media sentiment score of 0.59 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.
Journey Medical has higher revenue and earnings than Anebulo Pharmaceuticals. Journey Medical is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Anebulo Pharmaceuticals received 6 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 87.50% of users gave Anebulo Pharmaceuticals an outperform vote.
Anebulo Pharmaceuticals has a beta of -1, suggesting that its share price is 200% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
Anebulo Pharmaceuticals has a net margin of 0.00% compared to Journey Medical's net margin of -4.87%. Journey Medical's return on equity of -34.08% beat Anebulo Pharmaceuticals' return on equity.
28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 85.9% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 19.4% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Journey Medical beats Anebulo Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Anebulo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anebulo Pharmaceuticals Competitors List
Related Companies and Tools
